BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32922503)

  • 1. Bempedoic acid for the treatment of dyslipidemia.
    Marrs JC; Anderson SL
    Drugs Context; 2020; 9():. PubMed ID: 32922503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS; Sulaica EM; Beavers CJ
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Bempedoic Acid in Clinical Practice.
    Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review.
    Alam U; Al-Bazz DY; Soran H
    Diabetes Ther; 2021 Jul; 12(7):1779-1789. PubMed ID: 34037950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review.
    Goit R; Saddik SE; Dawood SN; Rabih AM; Niaj A; Raman A; Uprety M; Calero MJ; Villanueva MRB; Joshaghani N; Villa N; Badla O; Khan S
    Cureus; 2022 Oct; 14(10):e29891. PubMed ID: 36348882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
    Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
    BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
    Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
    J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
    Nguyen H; Akamnonu I; Yang T
    Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP).
    Banach M; Penson PE; Farnier M; Fras Z; Latkovskis G; Laufs U; Paneni F; Parini P; Pirro M; Reiner Ž; Vrablik M; Escobar C
    Prog Cardiovasc Dis; 2023; 79():2-11. PubMed ID: 36889490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant.
    Doggrell SA
    Expert Opin Pharmacother; 2023; 24(15):1673-1677. PubMed ID: 37496276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol.
    Pradhan A; Bhandari M; Vishwakarma P; Singh A; Perrone MA; Sethi R
    J Cardiovasc Dev Dis; 2023 Apr; 10(5):. PubMed ID: 37233162
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.